Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Bexsero

- PMLiVE

GSK to explore link between Shingrix and dementia risk in new UK research collaboration

More than 55 million people worldwide are currently living with the neurodegenerative disease

- PMLiVE

GSK’s five-in-one meningococcal vaccine Penmenvy granted FDA approval

It is hoped that the combination vaccine will simplify delivery and lead to higher uptake

- PMLiVE

GSK’s Jemperli combination approved by EC for expanded endometrial cancer use

Approximately 417,000 new cases of the disease are reported globally every year

- PMLiVE

GSK to expand gastrointestinal cancer pipeline with $1bn IDRx acquisition

The deal includes a TKI in development for gastrointestinal stromal tumours

- PMLiVE

GSK’s Jemperli receives positive CHMP opinion for expanded endometrial cancer use

Approximately 121,000 people are diagnosed with primary advanced or recurrent endometrial cancer each year in Europe

- PMLiVE

GSK gains exclusive option on DualityBio’s preclinical ADC in deal worth over $1bn

The candidate leverages DualityBio's platform against a gastrointestinal cancer target

- PMLiVE

GSK and Rgenta to develop RNA-targeting small molecules in deal worth up to $500m per target

The alliance is aimed at advancing treatments for multiple disease areas, including oncology

- PMLiVE

GSK granted EC approval for meningococcal disease vaccine Menveo

The fully liquid presentation is designed to simplify the vaccination process

- PMLiVE

GSK’s linerixibat shows promise in phase 3 primary biliary cholangitis trial

An estimated 510,000 people will be diagnosed with the rare liver disease globally by 2030

- PMLiVE

GSK and Vesalius partner on new Parkinson’s treatments in deal worth $650m

The alliance is aimed at developing treatments for Parkinson's and another neurodegeneration indication

- PMLiVE

GSK expands immunology pipeline by acquiring Chimagen’s CMG1A46 in deal worth $850m

The company plans to develop the candidate for autoimmune diseases such as lupus

- PMLiVE

GSK’s investigational antibiotic granted FDA priority review for urinary tract infections

Gepotidacin could be the first in a new class of oral antibiotics for uncomplicated UTIs in over 20 years

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links